Amgen is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley. Amgen is the world’s largest independent biotechnology firm. In 2013.It has two large selling products named Neulasta/Neupogen.In 1989 Amgen received approval for the first recombinant human erythropoetin product named Epogen for the treatment of anemia associated with chronic kidney failure.
Drug maker company Amgen Inc said its experimental drug to reduce thyroid levels in thyroid patients with chronic kidney disease met the main goal in a late-stage trial. The name of experimental drug is AMG 416.The drug, AMG 416, treats hyperparathyroidism patients. In which patients suffers from excessive secretion of parathyroid hormone, in kidney disease patients.
The results follow the recent announcement of positive data from a placebo-controlled late-stage study of AMG 416. Formerly name of AMG 416 was velcalcetide. In the AMG 416 group, 75.3 percent of patients achieved a > 30 percent reduction from baseline in PTH compared with 9.6 percent in the placebo arm, it shows a statistically significant result. Second point included the percent change from baseline during the EAP in serum phosphorus (P) concentration (mean changes of -9.63 and -1.60 percent among patients in the AMG 416 and placebo arms, respectively) and corrected calcium (cCa) concentration (mean changes of -6.69 and 0.58 percent among patients in the AMG 416 and placebo arms, respectively).It mean AMG 416 is doing very well their trails.So its a good news for Amgen as well as all other patients associated with chronic kidney failure.
About AMG 416
AMG 416 is a novel calcimimetic agent in Phase 3 clinical development for the treatment of SHPT that is administered intravenously in patients with CKD who are receiving hemodialysis. AMG 416 binds to and activates the calcium-sensing receptor on the parathyroid gland, thereby causing decreases in PTH. It is aphase 3 product in which clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or condition under study.